A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers

The primary objective of the study will be to measure safety. The primary endpoint measures to assess this objective will include but not be limited to * Frequency and nature of adverse events (AEs) reported or observed in participants; * Relatedness between AEs and vaccine administration; * Interventions or therapy required by participants experience vaccine related adverse events; * Resolution or outcome of AEs. Secondary Objectives and Endpoints Two main immunogenicity objectives will be assessed to include the number considered adequately immunized, and the magnitude and durability of titer responses.